Null Hub is alleviating the pain that tinnitus causes for so many people worldwide. Tinnitus is when you have the perception of ringing or whistling in your ear(s) when there is actually no external sound present. Tinnitus greatly affects people's living conditions and we have been working on creating a portable device that uses electrical nerve stimulation to alleviate this problem. The Null Beats will provide temporary tinnitus relief to allow people to experience silence again and regain their enjoyment of life.
Up until now, there are still about 3.2 billion people are at risk of Malaria. specifically, in 2015, 214 million new cases of malaria resulted to 438,000 deaths. Most of the deaths are from Africa and Southeast Asia. Rapid Diagnostic Test plays an essential role side by side with mosquito nets, indoor spraying, and medicine treatment to eliminate Malaria. It is estimated that the global Malaria testing need will be over 1 billion test per year. Most current malaria RDT have very high accuracy of about 99% with a low price of just under $1 per test. However, most of them are performed based on blood and only can give yes or no results; therefore, our team is aiming to design a novel malaria RDT which can give a quantitative result. Our device will use saliva, so it is noninvasive and based on (EIS) Electrochemical Impedance Spectroscopy technology, it can give out quantitative result that almost none of the existing commercialized products can offer.
If you want more energy, better health, and peace of mind; listen on. More than 50% of American suffers from sleep apnea and snoring, but everyone suffers from someone who snores. The compliance of the commonly prescripted continuous positive airway pressure device is 50% after the first year and continues to drop year after year. Curaflow aims to address that will a micro CPAP device that is motorless, tubeless, and maskless.
Many athletes often go through unbalanced workouts in which the muscles on their dominant side are much stronger than their weaker side, making them more susceptible to injuries. HANG2gether is developing a wearable electronic device that will obtain and process EMG signals during a workout in any environment. The device will send the recorded data to a smartphone application which will enable the user to monitor their muscle activity.
Ohana aims to reduce the growing rates of childhood obesity by motivating children, between the ages of 10-14, to exercise through the creation of fitness challenges and various exercise related games. Children can challenge their friends and family members and, in the process, build a support network to help them stay active while also enjoying themselves. Ohana creates an active and exercise oriented community that will help children to lead healthier lifestyles in the hopes of reducing childhood obesity.
Embrylux proposes a device that screens embryos by monitoring their metabolism. We will specifically measure the autofluorescence of NADH, an important biomolecule involved in the cell's production of energy, present in the cell. When laser light illuminates the embryo, NADH will autofluoresce or emit its own light. Through a process called fluorescence lifetime imaging microscopy (FLIM), our device will measure the lifetime of NADH or the time delay between the laser light and the autofluorescence. This data provides a unique signature that is reflective of the health of the embryo. Utilizing this signature, our device will then refer to a reference embryo viability library to determine the embryo’s health and probability of conception when implanted for in vitro fertilization.
Celiac disease, an autoimmune disorder, causes the body to attack itself upon gluten ingestion, resulting in intestinal damage. Damage related to celiac can lead to long-term health issues, including increased risk of cancer, osteoporosis, infertility, and heart and liver diseases. The only treatment is a strict gluten-free diet. The FDA allows labeling foods with gluten concentrations under 20 ppm as gluten-free. However, even trace amounts of gluten in food and other consumables can cause an immune reaction, despite lack of acute symptoms. To help celiac patients better manage their health, we have created a device that quantifies small amounts of gluten in food. Our device uses a lateral flow assay, similar to that in a pregnancy test, to detect gluten. This lateral flow is unique from previously developed tests, because it can inform the user of the specific quantity of gluten, rather than simply detect gluten concentration above a threshold. This allows the user to see if their food meets FDA labeling standards for gluten-free food. To do this, the lateral flow assay is read by a smartphone. Specifically, the emitted light from antibody-conjugated fluorophores, known as quantum dots, is imaged, and the detected intensity of a specific wavelength is integrated over the region of interest. The total intensity of light from the quantum dots is inversely correlated with the amount of gluten in the sample, allowing a quantified result. We are currently in the process of completing the final prototype and performing final testing on said prototype.
The majority of the skin biopsies that screen for skin cancer come back negative. This high rate of inaccuracy results in unnecessary pain and cost to the patients. As a result, Illume Medical is working to improve the way dermatologist screen for skin cancer. Our handheld device will be an enhanced dermatoscope to determine specific optical properties of the mole in question. These properties will help equip dermatologists to better determine whether a biopsy is needed or not, thus helping to reduce cost and unnecessary pain by reducing the number of unneeded biopsies.
Chemotherapy is currently monitored through palpation for breast cancer, which can take up to eighteen weeks to present changes. OncoSpect, our device, enables inexpensive, real-time, portable, and quantitative monitoring of chemotherapy in patients with cancers near the surface of the skin, such as breast cancer patients. Our goal is improve patient outlook by drastically reducing the time it takes to identify non-responding chemotherapy patients. This would allow Oncologist to make more educated decisions regarding the patient, preventing wasted money, time, and drugs. We hope to compliment existing systems in place at the clinic to prevent costly waiting time during chemotherapy treatment.
Syntr Health Tech is developing an innovative platform technology that is able to dissociate fat tissue and activate embedded mesenchymal stem cells. What sets our technology apart from the competition is the fact that our design is automated and is entirely mechanical, requiring no expensive solutions or reagents. The tissue processed by our device can be used for many applications ranging from cosmetics to advanced wound care. Our tissue processing system is called Aplyex. We aim to bring this product to market within the next three years.
We are celebrating the culmination of the Biomedical Device Design capstone course at UC Irvine. Join us over food and drinks as the senior design teams showcase their prototypes and compete for a chance to win BioENGINE Fellowships and Capstone Design Awards.
*Note: BioENGINE Fellowship candidates are also eligible for Capstone Design Awards
June 9, 2016, 4-7pm
UCI Applied Innovation
(5141 California Ave, Suite 200)